Sequential phenotyping of myeloma patients on chemotherapy: Persistence of activated t-cells and natural killer cells

Neil Elliot Kay, Martin M. Oken, Robert Kyle, Brian van Ness, Les Kalish, Traci Leong, Philip Greipp

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To better detail the status of functional T cell subsets and natural killer cells in multiple myeloma, we undertook a detailed immunophenotypic study of circulating mononuclear cells in myeloma. We studied myeloma patients entered on a large prospective, randomized ECOG chemotherapy trial EST 9486 for patients with newly diagnosed multiple myeloma. All patients were studied prior to entry and then two months after initiation of therapy (e.g. post two cycles of Vincristine, BCNU, melphalan, cyclophosphamide and prednisone (VBMCP)). The chemotherapy protocol was a three-arm protocol utilizing either VBMCP, VBMCP alternating with interferon, or VBMCP with intermittent high dose cyclophosphamide. The major findings in this analysis include significant reductions in the white blood cell count, total lymphocytes, T cell (CD3 + T helper (CD4+ and T suppressor (CD8+ cells, after 2 cycles of VBMCP. However, there was a relative sparing of Natural killer (CD16+ and activated T cell (CD2+ HLADR+ reduction in these same patients. In summary, only two cycles of combination chemotherapy resulted in significant reductions in white blood cell and lymphocyte counts in multiple myeloma patients. All cell types appear to have been reduced by chemotherapy except for activated T cells and natural killer cells. The impact of selective modulation of functional T cells subsets during therapy for patients with multiple myeloma is an important parameter which needs to be addressed in the overall approach to these patients.

Original languageEnglish (US)
Pages (from-to)351-354
Number of pages4
JournalLeukemia and Lymphoma
Volume16
Issue number3-4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Natural Killer Cells
Carmustine
Melphalan
Cyclophosphamide
Vincristine
Prednisone
Drug Therapy
Multiple Myeloma
T-Lymphocyte Subsets
T-Lymphocytes
Leukocyte Count
Lymphocyte Count
Combination Drug Therapy
Interferons
Lymphocytes
Therapeutics

Keywords

  • Chemotherapy activated T-cells
  • Myeloma
  • NK cells
  • Sequential phenotyping

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sequential phenotyping of myeloma patients on chemotherapy : Persistence of activated t-cells and natural killer cells. / Kay, Neil Elliot; Oken, Martin M.; Kyle, Robert; van Ness, Brian; Kalish, Les; Leong, Traci; Greipp, Philip.

In: Leukemia and Lymphoma, Vol. 16, No. 3-4, 1995, p. 351-354.

Research output: Contribution to journalArticle

Kay, Neil Elliot ; Oken, Martin M. ; Kyle, Robert ; van Ness, Brian ; Kalish, Les ; Leong, Traci ; Greipp, Philip. / Sequential phenotyping of myeloma patients on chemotherapy : Persistence of activated t-cells and natural killer cells. In: Leukemia and Lymphoma. 1995 ; Vol. 16, No. 3-4. pp. 351-354.
@article{9a0b7d1cb2df4751b7e3134624441c32,
title = "Sequential phenotyping of myeloma patients on chemotherapy: Persistence of activated t-cells and natural killer cells",
abstract = "To better detail the status of functional T cell subsets and natural killer cells in multiple myeloma, we undertook a detailed immunophenotypic study of circulating mononuclear cells in myeloma. We studied myeloma patients entered on a large prospective, randomized ECOG chemotherapy trial EST 9486 for patients with newly diagnosed multiple myeloma. All patients were studied prior to entry and then two months after initiation of therapy (e.g. post two cycles of Vincristine, BCNU, melphalan, cyclophosphamide and prednisone (VBMCP)). The chemotherapy protocol was a three-arm protocol utilizing either VBMCP, VBMCP alternating with interferon, or VBMCP with intermittent high dose cyclophosphamide. The major findings in this analysis include significant reductions in the white blood cell count, total lymphocytes, T cell (CD3 + T helper (CD4+ and T suppressor (CD8+ cells, after 2 cycles of VBMCP. However, there was a relative sparing of Natural killer (CD16+ and activated T cell (CD2+ HLADR+ reduction in these same patients. In summary, only two cycles of combination chemotherapy resulted in significant reductions in white blood cell and lymphocyte counts in multiple myeloma patients. All cell types appear to have been reduced by chemotherapy except for activated T cells and natural killer cells. The impact of selective modulation of functional T cells subsets during therapy for patients with multiple myeloma is an important parameter which needs to be addressed in the overall approach to these patients.",
keywords = "Chemotherapy activated T-cells, Myeloma, NK cells, Sequential phenotyping",
author = "Kay, {Neil Elliot} and Oken, {Martin M.} and Robert Kyle and {van Ness}, Brian and Les Kalish and Traci Leong and Philip Greipp",
year = "1995",
doi = "10.3109/10428199509049775",
language = "English (US)",
volume = "16",
pages = "351--354",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Sequential phenotyping of myeloma patients on chemotherapy

T2 - Persistence of activated t-cells and natural killer cells

AU - Kay, Neil Elliot

AU - Oken, Martin M.

AU - Kyle, Robert

AU - van Ness, Brian

AU - Kalish, Les

AU - Leong, Traci

AU - Greipp, Philip

PY - 1995

Y1 - 1995

N2 - To better detail the status of functional T cell subsets and natural killer cells in multiple myeloma, we undertook a detailed immunophenotypic study of circulating mononuclear cells in myeloma. We studied myeloma patients entered on a large prospective, randomized ECOG chemotherapy trial EST 9486 for patients with newly diagnosed multiple myeloma. All patients were studied prior to entry and then two months after initiation of therapy (e.g. post two cycles of Vincristine, BCNU, melphalan, cyclophosphamide and prednisone (VBMCP)). The chemotherapy protocol was a three-arm protocol utilizing either VBMCP, VBMCP alternating with interferon, or VBMCP with intermittent high dose cyclophosphamide. The major findings in this analysis include significant reductions in the white blood cell count, total lymphocytes, T cell (CD3 + T helper (CD4+ and T suppressor (CD8+ cells, after 2 cycles of VBMCP. However, there was a relative sparing of Natural killer (CD16+ and activated T cell (CD2+ HLADR+ reduction in these same patients. In summary, only two cycles of combination chemotherapy resulted in significant reductions in white blood cell and lymphocyte counts in multiple myeloma patients. All cell types appear to have been reduced by chemotherapy except for activated T cells and natural killer cells. The impact of selective modulation of functional T cells subsets during therapy for patients with multiple myeloma is an important parameter which needs to be addressed in the overall approach to these patients.

AB - To better detail the status of functional T cell subsets and natural killer cells in multiple myeloma, we undertook a detailed immunophenotypic study of circulating mononuclear cells in myeloma. We studied myeloma patients entered on a large prospective, randomized ECOG chemotherapy trial EST 9486 for patients with newly diagnosed multiple myeloma. All patients were studied prior to entry and then two months after initiation of therapy (e.g. post two cycles of Vincristine, BCNU, melphalan, cyclophosphamide and prednisone (VBMCP)). The chemotherapy protocol was a three-arm protocol utilizing either VBMCP, VBMCP alternating with interferon, or VBMCP with intermittent high dose cyclophosphamide. The major findings in this analysis include significant reductions in the white blood cell count, total lymphocytes, T cell (CD3 + T helper (CD4+ and T suppressor (CD8+ cells, after 2 cycles of VBMCP. However, there was a relative sparing of Natural killer (CD16+ and activated T cell (CD2+ HLADR+ reduction in these same patients. In summary, only two cycles of combination chemotherapy resulted in significant reductions in white blood cell and lymphocyte counts in multiple myeloma patients. All cell types appear to have been reduced by chemotherapy except for activated T cells and natural killer cells. The impact of selective modulation of functional T cells subsets during therapy for patients with multiple myeloma is an important parameter which needs to be addressed in the overall approach to these patients.

KW - Chemotherapy activated T-cells

KW - Myeloma

KW - NK cells

KW - Sequential phenotyping

UR - http://www.scopus.com/inward/record.url?scp=0028893360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028893360&partnerID=8YFLogxK

U2 - 10.3109/10428199509049775

DO - 10.3109/10428199509049775

M3 - Article

C2 - 7719242

AN - SCOPUS:0028893360

VL - 16

SP - 351

EP - 354

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -